EXHIBIT 10.41
EXECUTION VERSION
CONFIDENTIAL TREATMENT REQUESTED
UNDER 17 C.F.R. §§ 200.80(b)4, AND
240.24b-2
STOCK PURCHASE
AGREEMENT
by and among
IBIS BIOSCIENCES,
INC.,
ISIS PHARMACEUTICALS,
INC.
and
ABBOTT MOLECULAR
INC.
Dated:
December 17, 2008
TABLE OF
CONTENTS
|
|
|
Page No.
|
|
|
|
|
|
Section 1.
|
Definitions
|
1
|
|
|
|
|
|
Section 2.
|
Basic Transaction; Purchase Price
|
14
|
|
2.1
|
Sale and Transfer of the Remaining
Shares
|
14
|
|
2.2
|
Purchase Price
|
14
|
|
2.3
|
Earnout Payments
|
14
|
|
2.4
|
[Reserved]
|
15
|
|
2.5
|
Restricted Assets
|
16
|
|
|
|
|
|
Section 3.
|
Closing Of The Transaction
|
16
|
|
3.1
|
The Closing
|
16
|
|
3.2
|
Deliveries at the Closing
|
16
|
|
|
|
|
|
Section 4.
|
Conditions To Obligation To Close
|
17
|
|
4.1
|
Conditions to Obligation of AMI
|
17
|
|
4.2
|
Conditions to Obligation of Isis
|
19
|
|
|
|
|
|
Section 5.
|
Representations And Warranties
|
20
|
|
5.1
|
Representations and Warranties of
Isis
|
20
|
|
5.2
|
Representations and Warranties of AMI
|
36
|
|
|
|
|
|
Section 6.
|
Reserved
|
37
|
|
|
|
|
|
Section 7.
|
Pre-Closing Covenants
|
37
|
|
7.1
|
General
|
37
|
|
7.2
|
Affirmative Covenants of Isis and
Ibis
|
37
|
|
7.3
|
Negative Covenants of Isis
|
38
|
|
7.4
|
Notices and Consents
|
40
|
|
7.5
|
Full Access
|
40
|
|
7.6
|
Transition Assistance
|
41
|
|
7.7
|
Notice of Developments
|
41
|
|
7.8
|
Exclusivity
|
41
|
|
7.9
|
Indebtedness and Intercompany
Accounts
|
42
|
|
7.10
|
Distribution of Cash
|
42
|
|
7.11
|
[***] and [***]
|
42
|
|
7.12
|
Permitted Indebtedness
|
42
|
|
7.13
|
Bonus Arrangement Payments
|
43
|
|
|
|
|
|
Section 8.
|
Additional Agreements
|
43
|
|
8.1
|
Survival
|
43
|
|
8.2
|
Indemnification
|
43
|
|
8.3
|
Press Release and Announcements
|
46
|
|
8.4
|
Expenses
|
47
|
|
8.5
|
Setoff
|
47
|
i
|
8.6
|
Certain Tax Matters
|
47
|
|
8.7
|
Further Assurances
|
51
|
|
8.8
|
Confidentiality
|
51
|
|
8.9
|
Noncompetition and Nonsolicitation
|
53
|
|
8.10
|
Access to Books and Records
|
55
|
|
8.11
|
Employee and Related Matters
|
55
|
|
8.12
|
Consolidated Return
|
56
|
|
8.13
|
Isis Intellectual Property License
|
57
|
|
8.14
|
[***]
|
57
|
|
8.15
|
[***]
|
57
|
|
8.16
|
Fees for Transition Services
|
58
|
|
8.17
|
Updated Exhibits
|
58
|
|
|
|
|
|
Section 9.
|
Termination
|
58
|
|
9.1
|
Termination
|
58
|
|
9.2
|
Effect of Termination
|
58
|
|
|
|
|
|
Section 10.
|
Miscellaneous
|
59
|
|
10.1
|
No Third Party Beneficiaries
|
59
|
|
10.2
|
Entire Agreement
|
59
|
|
10.3
|
Successors and Assigns
|
59
|
|
10.4
|
Counterparts
|
59
|
|
10.5
|
Headings
|
59
|
|
10.6
|
Notices
|
59
|
|
10.7
|
Governing Law
|
61
|
|
10.8
|
Alternative Dispute Resolution
Procedure
|
61
|
|
10.9
|
Amendments and Waivers
|
61
|
|
10.10
|
Delays or Omissions
|
61
|
|
10.11
|
Incorporation of Exhibits and
Schedules
|
61
|
|
10.12
|
Construction
|
62
|
|
10.13
|
Remedies
|
62
|
|
10.14
|
Severability
|
62
|
|
10.15
|
No Other Compensation
|
63
|
ii
STOCK PURCHASE
AGREEMENT
THIS STOCK PURCHASE AGREEMENT (this
“ Agreement ”) is made and entered into as of
the 17 th day of December, 2008, by and among Isis
Pharmaceuticals, Inc., a Delaware corporation (“
Isis ”), Ibis Biosciences, Inc., a Delaware
corporation and Affiliate of Isis (“ Ibis ”),
and Abbott Molecular Inc., a Delaware corporation (“
AMI ”) and Affiliate of Abbott Laboratories, an
Illinois corporation (“ Abbott ”). AMI, Ibis and
Isis are sometimes referred to herein individually as a “
Party ” and collectively as the “ Parties
.”
WHEREAS, on January 30, 2008,
the Parties entered into the Master Agreement, a Call Option
Agreement and the Investor Rights Agreement, pursuant to which,
among other things, AMI acquired the Shares, the option,
exercisable in AMI’s sole discretion, to purchase the
Additional Shares from Ibis and the Call Option, for an aggregate
purchase price of $20,000,000;
WHEREAS, as of June 27, 2008,
the Parties entered into a Stock Subscription Agreement, pursuant
to which, among other things, AMI acquired the Additional Shares
for an aggregate purchase price of $20,000,000;
WHEREAS, Isis owns 1,000,000 shares
of Ibis’ Common Stock (the “ Remaining Shares
”);
WHEREAS, on December 12, 2008,
pursuant to the terms of the Call Option Agreement, AMI exercised
the Call Option, electing to acquire the Remaining Shares pursuant
to the terms hereof; and
WHEREAS, subject to the terms and
conditions set forth in this Agreement, Isis desires to sell to AMI
and AMI desires to acquire from Isis the Remaining
Shares.
NOW, THEREFORE, in consideration of
the mutual promises, representations, warranties, and covenants
hereinafter set forth and for other good and valuable
consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereby agree as follows:
Section 1.
DEFINITIONS
. Capitalized terms used and not
otherwise defined herein have the meanings ascribed to such terms
in this Section 1 .
(a)
“ Abbott
Transaction Team ” means the individuals listed on
Schedule 1(a) .
(b)
“
Additional Shares ” means 114,250 shares of Common
Stock acquired by AMI pursuant to the Stock Subscription Agreement,
as may be held from time to time by AMI and its permitted assigns,
which, together with the Shares, represent approximately 18.6% of
the issued and outstanding Common Stock.
(c)
“
Affiliate ” of an entity means any other entity that,
directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with such
first entity. For purposes of this definition only,
“control” (and, with correlative meanings, the terms
“controlled by” and “under common control
with”) means the
possession, directly or
indirectly, of the power to direct the management or policies of an
entity, whether through the ownership of voting securities or by
Contract relating to voting rights or corporate governance;
provided , that, with respect to Isis, the term
“Affiliate” shall specifically exclude
[***].
(d)
“
Applicable Law ” or “ Law ” means
all applicable common law, laws, constitutional provisions,
ordinances, statutes, rules, regulations, administrative rulings,
executive orders and other pronouncements having the effect of law
of any federal, national, multinational, state, provincial, county,
city or other political subdivision, agency or other body, domestic
or foreign, including but not limited to any applicable rules,
regulations, guidelines, or other requirements of Governmental
Authorities that may be in effect from time to time.
(e)
“
Applicable Rate ” means as of any particular date, the
prime rate as quoted in the Money Rates Section of The Wall
Street Journal , plus [***]%.
(f)
[***]
(g)
“ Bonus
Arrangement ” means the Special Bonus Opportunity
communicated to Ibis employees, pursuant to which a bonus pool of
[***] will be payable by Ibis to Ibis Employees in the event the
Closing is consummated.
(h)
“
Business ” means researching, developing,
manufacturing, selling, marketing, distributing and using a system,
process or reagents for the identification and/or quantitation of
nucleic acids or the performance of services relating to any of the
foregoing, as conducted by Ibis or by Isis, with respect to the
Division, on and prior to the Closing Date.
(i)
“
Business Day ” means any day other than a Saturday,
Sunday, or a day on which the banks in Chicago, Illinois are
authorized or obligated by Law to close.
(j)
“ Call
Option ” has the meaning ascribed to such term in the
Call Option Agreement.
(k)
“ Call
Option Agreement ” means that certain Amended and
Restated Call Option Agreement, dated as of November 18, 2008,
by and among Isis, Ibis and AMI.
(l)
“
Capital Stock ” means all capital stock,
equity or controlling interests and other securities in an issuer,
including, without limitation, options, warrants, depositary
receipts, stock appreciation or phantom stock rights or other
agreements or undertakings, including stock or securities
convertible or exchangeable for any shares of capital stock, equity
or controlling interests or other securities in an issuer or
containing any profit participation features or pursuant to which
such issuer is or could be bound to issue or repurchase any capital
stock, equity or controlling interests or other
securities.
(m)
“ Change
of Control ” means, with respect to any Person, the
occurrence of (i) any consolidation or merger of such Person
with or into any other Person, or any other corporate
reorganization or transaction (including the acquisition of Capital
Stock of such Person (or any rights to acquire, or securities
convertible into or exchangeable for, any such
2
Capital Stock)), whether or
not such Person is a party thereto, in which the stockholders or
equity-holders of such Person or other Persons controlling such
Person immediately prior to such consolidation, merger,
reorganization or transaction, own Capital Stock either
(A) representing directly, or indirectly through one or more
entities, less than fifty percent (50%) of the economic interests
in or voting power of such Person or other surviving entity
immediately after such consolidation, merger, reorganization or
transaction or (B) that does not directly, or indirectly
through one or more entities, have the power to elect a majority of
the entire board of directors or equivalent governing body of such
Person or other surviving entity immediately after such
consolidation, merger, reorganization or transaction or (ii) a
sale, lease, license or other disposition of all or a material
portion of the assets of such Person.
(n)
“
Claim ” means any claim, lawsuit, demand, audit,
investigation, charge, suit, hearing, notice of a violation,
litigation, action, proceeding, order, judgment, grievance, or
arbitration, whether civil, criminal, administrative or otherwise,
whether at law or in equity, or any inquiry likely to result in any
of the foregoing.
(o)
“
Code ” means the Internal Revenue Code of 1986, as
amended from time to time.
(p)
“ Common
Stock ” means the Common Stock of Ibis, par value $0.001
per share.
(q)
“
Confidential Information ” means all information and
any tangible embodiments thereof provided by or on behalf of the
Disclosing Party to the Receiving Party or to the Receiving
Party’s Representatives either in connection with the
discussions and negotiations pertaining to the Transaction
Documents or in the course of performing the Transaction Documents,
including without limitation: know-how; data; knowledge; practices;
processes; research and development plans; engineering designs and
drawings; research data; manufacturing processes and techniques;
scientific, manufacturing, marketing and business plans; and
financial and personnel matters relating to the Disclosing Party or
to its present or future products, sales, suppliers, customers,
employees, consultants, independent contractors, investors or
business; regardless of whether any of the foregoing are marked
“confidential” or “proprietary” or
communicated to the other by the Disclosing Party in oral, written,
graphic or electronic form. Notwithstanding the foregoing,
information of a Party will not be deemed Confidential Information
to the extent that the Receiving Party can show by competent proof
that such information:
(i)
is or becomes
generally available to the public other than as a result of an
unauthorized disclosure by the Receiving Party or its
Representatives;
(ii)
was available to
the Receiving Party or its Representatives on a non-confidential
basis prior to its disclosure by the Disclosing Party or its
Representatives;
(iii)
is or becomes
available to the Receiving Party or its Representatives from a
Person, other than the Disclosing Party or its
Representatives,
3
who is not bound
by a confidentiality obligation to the Disclosing Party or its
Representatives; or
(iv)
is independently
developed by the Receiving Party or its Representatives without
reference to or use of any Confidential Information of the
Disclosing Party.
(r)
“
Contract ” means any contract, lease, deed, mortgage,
license, instrument, note, commitment, undertaking, understanding,
indenture, joint venture, purchase order, service order and all
other agreements and arrangements, whether oral or
written.
(s)
“
Contribution Agreement ” means the Contribution
Agreement, dated as of July 31, 2007, by and between Isis and
Ibis.
(t)
“
Corporate Services Agreement ” means that certain
Corporate Services Agreement, dated as of July 31, 2007, by
and between Isis and Ibis.
(u)
[***]
(v)
“
Division ” means the Ibis Biosciences division of
Isis.
(w)
“
Earnout Threshold ” means $140 million minus all
commercial revenue for the period beginning on [***], as set forth
on Exhibit B , which has been prepared in accordance
with GAAP and Isis’ internal controls and procedures for
financial reporting and delivered pursuant to
Section 8.17 .
(x)
“
Employee Pension Benefit Plan ” has the meaning set
forth in Section 3(2) of ERISA.
(y)
“
Employee Welfare Benefit Plan ” has the meaning set
forth in Section 3(1) of ERISA.
(z)
“
Encumbrance ” means any mortgage, covenant,
hypothecation, condition, Claim, easement, encroachment, right of
way, restriction, option, lien (statutory or otherwise), pledge,
charge, license, security interest or encumbrance of any nature
whatsoever.
(aa)
“
Environmental Laws ” means any federal, state, local
or foreign statutes, ordinances, codes, treaties, or other Laws
(including, without limitation, the Comprehensive Environmental
Response, Compensation, and Liability Act, the Resource
Conservation and Recovery Act, the Clean Air Act, the Clean Water
Act, the Toxic Substances Control Act, the Oil Pollution Prevention
Act, the Federal Insecticide, Fungicide, & Rodenticide
Act, the Safe Drinking Water Act, the Hazardous Materials
Transportation Act, the Solid Waste Disposal Act, the Emergency
Planning and Community Right-to-Know Act, the Occupational Safety
and Health Act), including any regulations, rules, plans, other
criteria, policies or guidelines promulgated pursuant to such Laws,
and all common law, orders, judgments, decrees, judicial or agency
interpretations now or hereafter in effect relating to pollution,
the generation, production, installation, use, storage, treatment,
transportation, Release, threatened Release, investigation,
monitoring, remediation, cleanup, abatement, removal, or disposal
of Hazardous
4
Materials, noise control,
odor or the protection of public or workplace health or safety,
natural resources, or the environment.
(bb)
“
ERISA ” means the Employee Retirement Income Security
Act of 1974, as amended.
(cc)
“
Fundamental AMI Representations ” means those
representations and warranties of AMI set forth in
Section 5.2(a) (Power and Authority),
Section 5.2(b) (Enforceability),
Section 5.2(c) (Governmental Authority;
Consents), and Section 5.2(d) (No
Conflicts).
(dd)
“
Fundamental Isis Representations ” means those
representations and warranties of Isis set forth in Sections
5.1(a) (Power and Authority), 5.1(b)
(Enforceability), 5.1(c) (Governmental
Authority; Consents), 5.1(d) (No Conflicts),
5.2(e) (Due Organization; Qualification),
5.1(g) (Capitalization; Voting Rights), 5.1(j)
(Title to Properties and Tangible Assets; Liens, etc.),
5.1(k) (Sufficiency of Assets), 5.1(m)
(Compliance with Other Instruments), 5.1(t)(ii)
(Certain Balance Sheet Items) and 5.1(v)
(Brokers’ Fees).
(ee)
“
GAAP ” means United States generally accepted
accounting principles, applied on a consistent basis.
(ff)
“
Governmental Authority ” means any governmental or
quasi-governmental agency, department, bureau, office, center,
institute, court, commission or other unit of the government of the
United States of America or of any of its respective States or
local units of government thereof, or of a foreign sovereign or of
a provincial, regional or metropolitan government thereof,
including, without limitation, any Regulatory
Authority.
(gg)
“
[***] ” means the [***] identified on
Exhibit C , which has been prepared in accordance with
GAAP and Isis’ internal controls and procedures for financial
reporting, as updated and delivered pursuant to
Section 8.17 .
(hh)
“
[***] ” means any payments due to Ibis from a [***]
with respect to [***] awarded to Ibis or Contracts with Ibis, in
each case to the extent Ibis has performed the research or other
services described in the [***] or Contract, but not received
payment therefor prior to the Closing Date.
(ii)
“
Hazardous Materials ” means any substance, chemical,
solvent, compound, waste, residue, contaminant or other material
which is regulated by or forms the basis of liability now or
hereafter under any Environmental Law, including, without
limitation: (i) any “solid waste,”
“dangerous goods,” “hazardous waste,”
“hazardous substance,” “hazardous
material,” “extremely hazardous waste,”
“pollutant,” “contaminant,”
“hazardous constituent,” “special waste,”
“universal waste,” “toxic substance,” or
any other similar term or phrase as defined under any Environmental
Law; (ii) any petroleum, or petroleum products, byproducts or
breakdown products, including crude oil and any fraction thereof;
(iii) natural synthetic gas usable for fuel; (iv) any
asbestos, lead-based paint, polychlorinated biphenyl, mold, radon
gas, radioactive material or byproduct, isomer of dioxin, or any
material or thing containing or composed of such substance or
substances; and (v) any virus, bacteria, protozoa, parasite,
fungi, or other pathogen or any other substance, chemical, solvent,
compound, waste, residue,
5
contaminant or other
material which is hazardous, toxic, poisonous, reactive, corrosive
or otherwise may present a threat to human health, safety, natural
resources, wildlife or the environment.
(jj)
“ Ibis
Net Sales ” means:
(i)
the gross amount
billed by
Ibis or its Affiliates after the Closing for the sale or other
transfer or disposition of Products to, or performance of Services
for, non-Affiliate third parties in bona fide arms length
transactions, less deductions for:
A.
discounts, including cash discounts,
customary trade allowances or rebates actually taken, and
promotional discounts;
B.
credits or allowances given or made
for rejection, recall or return of previously sold Products and
rebates for previously provided Services;
C.
any Tax (including any Tax such as a
value added or similar Tax) levied on the sale, transportation or
delivery of Products when included on the invoice or other written
document between the parties as payable by the purchaser and
collectable by Ibis; and
D.
freight, postage, transportation,
insurance and duties on shipment of Product when included on the
invoice or written document between the parties as payable by the
purchaser and collectable by Ibis;
(ii)
[***];
and
(iii)
the amount of any
[***].
Ibis Net Sales calculations shall be applied as
provided above and modified as appropriate as follows:
1. When a Product is sold or
licensed by Ibis or its Affiliates or a Service is provided to a
non-Affiliate third party with whom Ibis or such Affiliate does not
deal at arms length, Ibis Net Sales for that Product or Service
shall equal an average of Ibis Net Sales for similar quantities of
Products sold or Services provided within the same calendar quarter
in an arms length transaction in the same geographic market and
class of purchasers or Service recipients as the non-arms length
purchaser or Service recipient.
2. In the event that a Product is
sold or a Service provided in combination with any other
product(s) or service(s), Ibis Net Sales with respect to the
Product or Service of the combination shall be determined by the
fraction A over A + B in which “A” is Ibis Net Sales of
the Product or Service portion of the combination when sold
separately during the applicable calendar quarter, and
“B” is Ibis Net Sales of the other product(s) or
service(s) of the combination product or service when sold
separately during the applicable calendar quarter.
6
3. In the event a Product or Service
is incorporated into a profile in which said Product or Service
contributes only a small proportion of the value of the total
package, but the adjustment set forth in paragraph 2, above is
impractical or if similar quantities of product(s) are not
sold or similar quantities of Services are not provided pursuant to
paragraph 1, above, then the Parties shall negotiate in good faith
to establish an equitable adjustment to Ibis Net Sales for such
Product or Service to fairly reflect the proportion of the value of
the profile contributed by the Product or Service or the value of
the Product or Service.
(kk)
“
Indebtedness ” means (i) all indebtedness or
other obligations of Ibis for borrowed money, whether current,
short-term or long-term, secured or unsecured, and all accrued
interest, premiums, penalties and other obligations relating
thereto, (ii) all indebtedness of Ibis for the deferred
purchase price of property or services which is not evidenced by
accounts payable incurred in the ordinary course of business,
(iii) all existing lease obligations of Ibis under leases
which are capital leases in accordance with GAAP, (iv) any
liability of Ibis under deferred compensation plans, phantom stock
plans, severance or bonus plans, or any change in control or
similar payment or increased cost which is triggered or made or
will be made payable by Ibis as a result of the transactions
contemplated hereby, other than the Bonus Arrangement, (v) any
off balance sheet financing of Ibis, (vi) any payment
obligations of Ibis in respect of banker’s acceptances or
letters of credit, (vii) any liability of Ibis with respect to
interest rate swaps, collars, caps and similar hedging obligations,
(viii) all obligations of Ibis arising under or with respect
to any conditional sale or other title retention agreement with
respect to property acquired by Ibis, (ix) past due or
deferred rent of Ibis, (x) the amount of accounts payable owed
by Ibis to any Person that have not been paid within 45 days of the
date of invoice thereof (xi) all “cut” but
“uncashed” checks of Ibis outstanding as of the
Closing, (xii) any indebtedness referred to above of any Person
which is either guaranteed by, or secured by a security interest
upon any property owned by, Ibis and (xiii) accrued and unpaid
interest of, and prepayment premiums, penalties or similar
contractual charges arising as a result of the discharge of any
such foregoing obligation.
(ll)
“
Intellectual Property ” means all of the following in
any jurisdiction throughout the world: (i) patents,
patent applications and patent disclosures and statutory invention
registrations, including reissues, divisions, continuations,
continuations in part, extensions and reexaminations thereof;
(ii) trademarks, service marks, trade dress, trade names,
corporate names, logos and slogans (and all translations,
adaptations, derivations and combinations of the foregoing) and
Internet domain names any and all common law rights and
registrations and applications for the registration thereof, and
all extensions and renewals of any of the foregoing;
(iii) copyrights and copyrightable works (including Software),
registered copyrights and copyright applications, mask works, net
lists and schematics; (iv) confidential and proprietary
information including technology, know-how, trade secrets,
unpatented inventions, ideas, algorithms and processes (including,
without limitation, manufacturing and production processes and
techniques, drawings, specifications, designs, plans, proposals,
test data including pharmacological, biological, chemical,
biochemical, toxicological and clinical test data, analytical and
quality control data, stability data and customer and supplier
lists and related information); (v) other intellectual
property and proprietary information and (vi) all copies and
tangible embodiments of the foregoing, such as instruction manuals,
laboratory notebooks, prototypes, samples, specimens, studies and
summaries.
7
(mm)
“
Investment Date ” means January 23,
2008.
(nn)
“
Investment Documents ” means the Master Agreement, the
Call Option Agreement, the Investor Rights Agreement and the Stock
Subscription Agreement.
(oo)
“
Investor Rights Agreement ” means that certain
Investor Rights Agreement, dated as of the Investment Date, by and
among Isis, Ibis and AMI.
(pp)
“ Isis
Licensed Intellectual Property ” means the Intellectual
Property set forth on Exhibit D .
(qq)
[***]
(rr)
“
Knowledge ” and terms of similar meaning (including,
without limitation, “is aware of”) mean (i) with
respect to Ibis and Isis, the actual knowledge of any of the
individuals set forth on Schedule 1(rr) , after due
investigation, including, without limitation, inquiry of Persons
with subject matter knowledge, provided that (A) solely
for purposes of Sections 5.1(l)(v) , 5.1(l)(vi)
and 5.1(l)(ix) , “Knowledge” and terms of
similar meaning (including, without limitation, “is aware
of”) mean the actual knowledge of any employee of Ibis or
Isis, after due investigation, including, without limitation,
inquiry of Persons with subject matter knowledge and
(B) solely for purposes of Section 5.1(l) ,
inquiry of Persons with subject matter knowledge shall include
inquiry of the outside counsel involved in the development or
prosecution of the Business IP or who conducted ‘freedom to
operate analyses’ identified on Schedule 1(rr) and
(ii) with respect to AMI, the actual knowledge of any of the
individuals set forth on Schedule 1(rr) , after due
investigation.
(ss)
“
Licenses ” means all licenses, permits, certificates
of authority, variances, authorizations, approvals, registrations,
franchises, orders and similar consents issued by any Governmental
Authority or other Person, provided , that the term License
shall not include any license or other right to use any
Intellectual Property.
(tt)
“
Loss ” means any loss, liability, demand, Claim,
action, cause of action, cost, damage, diminution in value,
deficiency, Tax, penalty, fine or expense (including interest,
penalties, reasonable attorneys’ fees and expenses and all
amounts paid in investigation, defense or settlement of any of the
foregoing and the enforcement of any related rights), whether or
not arising out of third party claims.
(uu)
“
Management Presentations ” means the Management
Presentations of Ibis delivered to AMI pursuant to
Section 2(h) of the Master Agreement.
(vv)
“ Master
Agreement ” means that certain Strategic Alliance Master
Agreement, dated as of the Investment Date, by and among Isis, Ibis
and AMI.
(ww)
“
Multiemployer Plan ” has the meaning set forth in
Section 3(37) of ERISA.
(xx)
“
Offering Memorandum ” means the Offering Memorandum of
Ibis, dated November 2006, as made available to
AMI.
8
(yy)
“
[***] ” means any payments, including, but not limited
to royalty payments, license fees and milestone payments that are
made by non-Affiliate third parties to [***] (or any of its
Affiliates) in bona fide arms length transactions in consideration
for one or more license or equivalent agreements that grant such
non-Affiliate third party rights under any [***] (i) make,
have made, use, sell, offer for sale or import any products by
[***] to another party for a fee, in each case, where any of the
foregoing conduct by such non-Affiliate third party in the absence
of such rights under license or equivalent agreement would infringe
(directly, contributorily, by inducement or otherwise),
misappropriate or otherwise conflict with any [***].
(zz)
“
Permitted Encumbrances ” means (i) liens for
current property Taxes not yet due and payable,
(ii) Encumbrances arising in connection with and solely as a
result of Permitted Indebtedness and (iii) except with respect
to Intellectual Property, other imperfections of title,
restrictions or Encumbrances, if any, which imperfections,
restrictions or Encumbrances do not, individually or in the
aggregate, impair the continued use and operation of the assets
used in the operation of the Business and do not affect the
merchantability of the title to such assets to which they
relate.
(aaa)
“
Permitted Indebtedness ” means (i) accounts
payable incurred in the ordinary course of business that are paid
within forty-five (45) days of the date of invoice thereof,
(ii) Indebtedness arising from existing and future lease
obligations of Ibis under equipment leases that are capital leases
in accordance with GAAP so long as the collateral for such capital
leases is limited to the equipment acquired and the aggregate
amount of such capital leases does not exceed [***] and
(iii) Indebtedness incurred pursuant to the Corporate Services
Agreement or the Contribution Agreement.
(bbb)
“
Person ” means an individual, a partnership, a
corporation, an association, a limited liability company, a joint
stock company, a trust, a joint venture, an unincorporated
organization, or a Governmental Authority (or any department,
agency, or political subdivision thereof).
(ccc)
“
Pre-Closing Tax Period ” means a Tax period ending on
or before the Closing Date and the portion through the end of the
Closing Date for any Tax period that includes (but does not end on)
the Closing Date.
(ddd)
“
Post-Closing Tax Period ” means a Tax period beginning
after the Closing Date and, for any Tax period that includes (but
does not end on) the Closing Date, the portion of such period
beginning after the Closing Date.
(eee)
“
Products ” means the T5000 Biosensor System (including
kits) and any Successor Products.
(fff)
“
Purchase Offer ” means any proposal or offer from any
Person (other than AMI and its Affiliates in connection with the
transactions contemplated hereby) or any agreement or offer
relating to any (i) reorganization, liquidation, dissolution,
share exchange, business combination or recapitalization of Ibis,
(ii) merger or consolidation involving Ibis,
(iii) purchase or sale of any assets or Capital Stock of Ibis
(other than the purchase and sale of inventory and capital
equipment in the ordinary course of business),
(iv) distribution of Ibis’
9
existing or future products,
(v) licensing of any Business IP from Ibis or (vi) any
other transaction or business combination involving Ibis or its
business or assets which would reasonably be expected to interfere
with, impede or materially delay the transactions contemplated by
the Transaction Documents or dilute the benefits thereof to AMI and
its Affiliates.
(ggg)
“ Real
Property ” means the Leased Real Property.
(hhh)
“
Regulatory Authority ” means any Governmental
Authority that has responsibility for granting any licenses or
approvals or granting pricing and/or reimbursement approvals
necessary for the marketing and sale of medical devices or
diagnostic products, including without limitation, the FDA, the
European Medicines Agency and the United States Department of
Health and Human Services.
(iii)
“
Release ” means any spilling, leaking, pumping,
pouring, emitting, emptying, discharging, injecting, escaping,
leaching, dumping, depositing, disposing or other release into the
environment (including the abandonment or discarding of barrels,
drums, containers or other closed receptacles), including any
dispersal, migration or other movement of any substance through or
in air, soil, surface water, groundwater or property.
(jjj)
“
Representatives ” means with respect to any Person,
such Person’s employees, directors, officers, Affiliates and
authorized agents.
(kkk)
“
Schedule ” means any of the Disclosure Schedules
delivered to AMI herewith and incorporated herein pursuant to
Section 10.11 hereof.
(lll)
“
SEC ” or “ Commission ” means the
United States Securities and Exchange Commission.
(mmm)
“
Securities Act ” means the Securities Act of 1933, as
amended.
(nnn)
“
Services ” means using any Business IP to analyze
samples containing nucleic acids and providing the results of such
analyses to a third party for a fee.
(ooo)
“
Shares ” means 114,251 shares of Common Stock issued
to AMI pursuant to the Master Agreement, as may be held from time
to time by AMI and its permitted assigns, representing
approximately 10.25% of the issued and outstanding Common
Stock.
(ppp)
“
Software ” means any and all (i) computer
programs, libraries, firmware and middleware, including any and all
software implementations of algorithms, models and methodologies,
whether in source code or object code, (ii) databases and
compilations, including any and all data and collections of data,
whether machine readable or otherwise, (iii) descriptions,
flow-charts and other work product used to design, plan, organize
and develop any of the foregoing and (iv) all programmer and
user documentation, including user manuals and training materials,
relating to any of the foregoing.
(qqq)
“ Stock
Subscription Agreement ” means the Stock Subscription
Agreement dated as of June 27, 2008, by and among Ibis, Isis
and AMI.
10
(rrr)
“
Subsidiary ” means, with respect to a Person, any
corporation, limited liability company, partnership, association or
other business entity of which (i) if a corporation, a
majority of the total voting power of shares of stock entitled
(without regard to the occurrence of any contingency) to vote in
the election of directors, managers or trustees thereof is at the
time owned or controlled, directly or indirectly, by such Person or
one or more of the other Subsidiaries of such Person or a
combination thereof, or (ii) if a limited liability company,
partnership, association or other business entity, a majority of
the partnership or other similar ownership interest thereof is at
the time owned or controlled, directly or indirectly, by such
Person or one or more Subsidiaries of such Person or a combination
thereof. For purposes hereof, a Person shall be deemed to
have a majority ownership interest in a limited liability company,
partnership, association or other business entity if such Person
shall be allocated a majority of limited liability company,
partnership, association or other business entity gains or losses
or shall be or control any managing director or general partner of
such limited liability company, partnership, association or other
business entity.
(sss)
“
Successor Products ” means any product that
(i) relies upon [***] and determination of [***] by [***]
using either the Ibis [***], each as in existence in the Business
at the Closing, including as may be modified subsequently by AMI or
(ii) is described in U.S. Patent No.’s
[***].
(ttt)
“ T5000
Biosensor System ” means the biosensor platform generally
known as the T5000 Biosensor System, together with all equipment,
hardware, Software, systems and other materials required for its
use, or provided or recommended by Ibis, Isis or any of their
respective Affiliates for its use, as well as all prior versions of
the T5000 Biosensor System, including such systems known as
“TIGER.”
(uuu)
“
Tax ” means any federal, state, local, or foreign
income, gross receipts, license, payroll, employment, excise,
severance, stamp, occupation, premium, windfall profits,
environmental, customs and other duties, capital stock, franchise,
profits, withholding, social security, unemployment, disability,
real property, personal property, sales, use, transfer,
registration, value added, alternative or add-on minimum,
estimated, or other tax of any kind whatsoever, including any
interest, penalty, or addition thereto, whether disputed or not,
and including any obligation to indemnify or otherwise assume or
succeed to the Tax liability of any other Person.
(vvv)
“ Tax
Return ” means any return, declaration, report, claim for
refund, or information return or statement relating to Taxes,
including any schedule or attachment thereto, and including any
amendment thereof.
(www)
“ Third
Party Payments ” means payments, including, but not
limited to damage awards, royalty payments, license fees and
milestone payments, that are made by [***] to a third party, which
are based upon making, having made, using, selling, offering for
sale or importing [***], under order of a Governmental Authority or
license agreements or equivalent agreements with the third party to
obtain rights under any United States or foreign copyrights, patent
applications or patents that are [***] to make, have made, use,
sell, offer for sale or import any [***].
11
(xxx)
“
Transaction Documents ” means the Master Agreement,
the Investor Rights Agreement, the Stock Subscription
Agreement, the Call Option Agreement,
the Transition Services Agreement and this Agreement.
(yyy)
“
Transfer ” means, with respect to Capital Stock, any
sale, pledge, hypothecation, assignment, Encumbrance or other
transfer or disposition, whether directly, indirectly, voluntarily,
involuntarily, by operation of Law, pursuant to judicial process or
otherwise and, when the context so requires, the act of doing any
of the foregoing.
Section references for
definitions of defined terms defined in the body of this Agreement
rather than in this Section 1 .
|
Defined Term
|
|
Section
|
|
|
|
|
|
“§ 338(h)(10) Election”
|
|
8.6(g)
|
|
“Abbott”
|
|
Preamble
|
|
“ADR”
|
|
10.8
|
|
“Agreement”
|
|
Preamble
|
|
“AMI”
|
|
Preamble
|
|
“AMI Group”
|
|
8.2(a)
|
|
“AMI Proceeding”
|
|
8.6(e)(ii)
|
|
“Applicable AMI
Proceeding”
|
|
8.6(e)(ii)
|
|
[***]
|
|
|
|
“Business IP”
|
|
5.1(l)(i)
|
|
“Closing”
|
|
3.1
|
|
“Closing Date”
|
|
3.1
|
|
“Closing Purchase Price”
|
|
2.2
|
|
“Disclosing Party”
|
|
8.8(a)
|
|
“Disclosure Schedules”
|
|
Section 5
|
|
“Earnout Payments”
|
|
2.3(e)
|
|
“Earnout Period”
|
|
2.3(a)
|
|
“Earnout Rate”
|
|
2.3(a)
|
|
“ERISA Affiliate”
|
|
5.1(p)(ii)
|
|
“ERISA Plans”
|
|
5.1(p)(ii)
|
|
“FDA”
|
|
5.1(q)(i)
|
|
“Financial Statements”
|
|
5.1(t)(i)
|
|
“Government Contracts”
|
|
5.1(l)(ii)
|
12
|
“HSR Act”
|
|
4.1(d)
|
|
“Ibis”
|
|
Preamble
|
|
“Ibis Contracts”
|
|
5.1(x)(i)
|
|
“Ibis Employees”
|
|
8.11(a)
|
|
“Indemnified Party”
|
|
8.2(e)
|
|
“Indemnifying Party”
|
|
8.2(e)
|
|
“Insurance Policies”
|
|
5.1(y)
|
|
“IP Contracts”
|
|
5.1(l)(ii)
|
|
“Isis”
|
|
Preamble
|
|
“Isis Proceeding”
|
|
8.6(e)(i)
|
|
“Isis Retirement Plans”
|
|
8.11(d)
|
|
“Leased Real Property”
|
|
5.1(w)(ii)
|
|
“Leasehold Improvements”
|
|
5.1(w)(ii)
|
|
“Leases”
|
|
5.1(w)(ii)
|
|
“Material Adverse Effect”
|
|
4.1(j)
|
|
“Material Licenses”
|
|
5.1(q)(ii)
|
|
“Most Recent Balance
Sheet”
|
|
5.1(t)(i)
|
|
“Noncompete Period”
|
|
8.9(a)
|
|
“Nonsolicitation Period”
|
|
8.9(c)
|
|
“Note”
|
|
7.12
|
|
“Parties”
|
|
Preamble
|
|
“Party”
|
|
Preamble
|
|
“Plans”
|
|
5.1(p)(ii)
|
|
“Pre-Existing Business”
|
|
8.9(b)
|
|
[***]
|
|
|
|
“Purchase Price”
|
|
2.2
|
|
“Rate Reserve Limit”
|
|
8.15
|
|
[***]
|
|
|
|
“Receiving Party”
|
|
8.8(a)
|
|
“Remaining Shares”
|
|
Recitals
|
|
“Restricted Assets”
|
|
2.5
|
|
“Seller Group”
|
|
8.2(b)
|
|
“Special AMI Claims”
|
|
8.2(e)(iii)
|
13
|
“Straddle Period”
|
|
8.6(c)(ii)
|
|
“Third Party Claim”
|
|
8.2(e)
|
|
“Transaction Value”
|
|
2.2
|
|
“Transition Services
Agreement”
|
|
4.1(k)
|
|
“WARN Act”
|
|
8.11(b)
|
Section 2.
BASIC TRANSACTION; PURCHASE
PRICE.
2.1
Sale and Transfer of the
Remaining Shares .
Subject to the terms and conditions of this Agreement, at the
Closing, Isis shall sell, convey, assign, transfer and deliver to
AMI all of the Remaining Shares, free and clear of all
Encumbrances, and AMI shall purchase, acquire and accept the
Remaining Shares from Isis.
2.2
Purchase Price.
The purchase price (the
“ Purchase Price ”) for the Remaining Shares
shall be equal to (i) $175,000,000 (the “ Transaction
Value ”), minus (ii) the amount of any Indebtedness of
Ibis as of the Closing (not including the amount of any
Indebtedness that is Permitted Indebtedness under clauses (i) or
(ii) of the Permitted Indebtedness definition), plus (iii)
the Earnout Payments. The “ Closing Purchase
Price ” is an amount equal to (x) the Transaction Value,
minus (y) the amount of any Indebtedness of Ibis as of the Closing
(not including the amount of any Indebtedness that is Permitted
Indebtedness under clauses (i) or (ii) of the Permitted
Indebtedness definition).
2.3
Earnout Payments.
(a)
Subject to
Sections 2.3(e) and 2.3(g) , from and after the
Closing Date until December 31, 2025 (the “ Earnout
Period ”), Ibis will pay to Isis an amount equal to five
percent (5%) (the “ Earnout Rate ”) of
cumulative Ibis Net Sales that are (i) in excess of the
Earnout Threshold and (ii) less than or equal to
$2,100,000,000. Such amounts payable to Isis will be reduced
by an amount equal to [***] of any [***], but in no event will such
amounts for such Ibis Net Sales be less than two and a half percent
(2.5%) of such cumulative Ibis Net Sales.
(b)
For cumulative
Ibis Net Sales during the Earnout Period that are in excess of
$2,100,000,000, the Earnout Rate will reduce from 5% to 3%.
The corresponding amounts payable to Isis will be reduced by an
amount equal to [***] of any [***], but in no event will such
amounts for such Ibis Net Sales be less than one and a half percent
(1.5%) of such cumulative Ibis Net Sales.
(c)
In calculating
the amount of any reduction to the earn-out payments permitted by
the second sentence of either Section 2.3(a) or
Section 2.3(b) that result from any [***] that
are [***], the amount of such [***] [***] will be [***] of the
Earnout Period from the date of such [***]. For example, if
Ibis makes a [***] in the form of [***] equal to [***] to [***]
which, in AMI’s reasonable judgment was [***] and such [***]
was made in 2015, then, in each calendar quarter, Ibis would be
able to reduce the corresponding amounts
14
payable for such quarter by
[***], in each case subject to the applicable 2.5% or 1.5% floor
under Section 2.3(a) or
Section 2.3(b) .
(d)
The earnout
amounts described in Sections 2.3(a) and 2.3(b)
will be payable on a quarterly basis, within [***] days after
the last day of each calendar quarter, by wire transfer of
immediately available funds to an account designated by Isis.
Within [***] [***] days of the end of each calendar quarter, Ibis
will deliver to Isis its non-binding, preliminary, good faith
estimate of Ibis Net Sales for such calendar quarter. All
amounts included in Ibis Net Sales shall be in United States funds
collectible at par in Chicago, Illinois. With respect to
Product or Service revenues, [***], or [***] that are used in the
calculation of Ibis Net Sales and are in monies other than United
States dollars, the amount to be used will first be determined in
the foreign currency of the country for such monies and then
converted into equivalent United States funds using the same
conversion methodology that Abbott uses to prepare its financial
statements filed with the SEC.
(e)
Notwithstanding
the foregoing, Sections 2.3(a) through 2.3(c) ,
(i) the earnout amounts described in Sections 2.3(a)
and 2.3(b) will be payable only on cumulative
Ibis Net Sales in excess of the Earnout Threshold, (ii) no
such earnout amounts will be payable in any calendar year in which
total Ibis Net Sales in such calendar year were less than or equal
to [***], (iii) in any calendar year in which Ibis Net Sales
exceed [***] and cumulative Ibis Net Sales exceed the Earnout
Threshold, the earnout amounts described in Sections 2.3(a)
and 2.3(b) will be payable with respect to all
Ibis Net Sales in such calendar year which are in excess of the
Earnout Threshold and (iv) all Ibis Net Sales, regardless of
whether earnout amounts are payable thereon, will be included in
cumulative Ibis Net Sales for purposes of determining the
applicable Earnout Rate. For example, if Ibis Net Sales in
each of the calendar years 1 and 3 are equal to [***] and Ibis Net
Sales in each of the calendar years 2 and 4 are equal to [***], no
earnout amounts would be payable in calendar years 1 through 3, but
earnout amounts would be payable with respect to the entire [***]
in Ibis Net Sales in calendar year 4. The earnout amounts
payable by Ibis to Isis pursuant to this Section 2.3
are referred to herein as the “ Earnout Payments
.”
(f)
Ibis shall
maintain its books and records used to determine Ibis Net Sales,
[***], and [***] for a period of three (3) years from the date
of the Earnout Payment to which they pertain. Ibis shall make
such books and records available for inspection by third party
representatives of Isis approved in writing (which approval shall
not be unreasonably withheld, conditioned or delayed) once per
calendar year at reasonable times and upon reasonable written
advance notice from Isis. All information contained in these
books and records shall be Confidential Information and will be
used only for the purpose of determining the accuracy of
Ibis’ calculation of any Earnout Payment.
(g)
Notwithstanding
any provision of this Agreement or any other Transaction Document
to the contrary, except with respect to any [***] arising as a
result of or in connection with a breach of the representations and
warranties set forth in Section 5.1(l)(v) , the Earnout
Payment reductions set forth in Sections 2.3(a) and
2.3(b) will be the AMI Group’s sole and
exclusive remedy for any [***].
2.4
[ Reserved ]
15
2.5
Restricted Assets
. Notwithstanding any other
provision in this Agreement to the contrary, this Agreement shall
not constitute an agreement to assign or transfer any interest in
any Contract, asset, claim, right or benefit the assignment or
transfer of which is otherwise contemplated by the transactions
contemplated by this Agreement to the extent such assignment or
transfer (or attempt to make such an assignment or transfer)
without the consent or approval of a third party would constitute a
breach or other contravention of the rights of such third party, or
affect adversely the rights of any Party or their Affiliates
thereunder (such assets being collectively referred to herein as
“ Restricted Assets ”). Any assignment or
transfer of a Restricted Asset shall be made subject to such
consent or approval being obtained. If any such consent or
approval is not obtained prior to the Closing, (a) the assigning or
transferring Party shall continue to use its commercially
reasonable efforts to cooperate with the other Party in attempting
to obtain any such consent or approval and (b) establish
alternative arrangements (such as a license, sublease, subcontract
or operating agreement) until such time as such consent or approval
has been obtained which results in the assignee or transferee Party
receiving all the benefits and bearing all the burdens with respect
to any such Restricted Asset (subject to Section 8.4 ,
pursuant to which Isis shall be liable for and pay all
out-of-pocket costs and expenses associated with obtaining third
party consents associated with any Ibis Contract or Restricted
Asset in excess of [***] in the aggregate).
Section 3.
CLOSING OF THE
TRANSACTION.
3.1
The Closing
. Subject to the satisfaction
or waiver of the conditions set forth herein, the closing of the
transactions contemplated by this Agreement (the “
Closing ”) shall take place at the offices of Kirkland
& Ellis LLP in Chicago, Illinois, at 10:00 a.m. Central Time on
the third Business Day following the satisfaction or waiver of all
conditions to the obligations of the Parties to consummate the
transactions contemplated, or on such other date, time and place as
the Parties may mutually agree in writing (the “Closing
Date”), and the Closing shall be deemed effective as of 12:01
a.m. Pacific Time on the Closing Date.
3.2
Deliveries at the Closing. At
the Closing:
(a)
Isis shall
deliver to AMI (i) the various certificates, agreements,
instruments and documents referred to in Section 4.1
below and (ii) such other instruments of sale, transfer,
conveyance and assignment as AMI reasonably may
request;
(b)
AMI shall deliver
to Isis (i) the Closing Purchase Price, via wire transfer of
immediately available funds to an account designated in writing by
Isis at least five (5) Business Days prior to the Closing
Date, and (ii) the various certificates, agreements,
instruments and documents referred to in Section 4.2
below;
(c)
Isis shall
deliver to Ibis all books, records and other materials of Ibis or
related to or used by Ibis in the Business, including the corporate
minute book and stock ledger for Ibis (unless otherwise
specifically set forth in the Transition Services Agreement);
and
(d)
Isis shall
deliver to AMI one or more compact discs or other electronic media
containing the contents of the electronic dataroom maintained by
Isis at [***] as of the date that is three Business Days prior to
the date hereof, together with a certificate of an
16
authorized officer
certifying that such compact discs contain true, accurate and
complete copies of the materials in such dataroom as of such
date.
Section 4.
CONDITIONS TO OBLIGATION TO
CLOSE.
4.1
Conditions to Obligation of
AMI . The
obligation of AMI to consummate the transactions to be performed by
it in connection with the Closing is subject to satisfaction of the
following conditions:
(a)
Each of the
representations and warranties of Isis set forth in this Agreement
shall be true and correct in all material respects at and as of the
date hereof and as of the Closing Date (disregarding any
materiality or Material Adverse Effect qualifications contained
therein, other than such qualifications contained in
Section 5.1(aa) ); provided , that any
representation or warranty of Isis set forth in this Agreement that
is made as of any date other than the date hereof shall be true and
correct as of such date in all material respects (disregarding any
materiality or Material Adverse Effect qualifications contained
therein).
(b)
Each of Isis and
Ibis shall have performed and complied in all material respects
with each of their covenants hereunder through the
Closing.
(c)
No Claim shall be
pending before any court, arbitrator, other body or administrative
agency of any Governmental Authority wherein an unfavorable
injunction, judgment, order, decree, ruling or charge would prevent
consummation of any of the transactions contemplated by this
Agreement (and no such injunction, judgment, order, decree, ruling
or charge shall be in effect).
(d)
All filings with
and authorizations and approvals of Governmental Authorities that
are required for the consummation of the transactions contemplated
hereby shall have been duly made and obtained on terms reasonably
satisfactory to AMI. Without limiting the generality of the
foregoing, all applicable waiting periods (and any extensions
thereof) under the Hart Scott Rodino Antitrust Improvements Act of
1976, as amended (the “ HSR Act ”), shall have
expired or otherwise been terminated.
(e)
Isis shall have
delivered to AMI (i) a certificate from an officer of Isis to
the effect that each of the conditions specified in
Section 4.1(a) , Section 4.1(b) and,
except for the matters expressly set forth on the Disclosure
Schedules, Section 4.1(j) , is satisfied in all
respects, (ii) a copy of the resolutions of the governing body
of each of Isis and Ibis approving the transactions contemplated by
this Agreement, certified by an officer of each of Isis and Ibis,
respectively, (iii) certificates from appropriate authorities,
dated as of or about the Closing Date, as to the good standing and
qualification to do business of Ibis in its jurisdiction of
incorporation, (iv) such other documents or instruments as are
required to be delivered at the Closing pursuant to the terms
hereof and (v) such other documents or instruments as AMI
reasonably requests to effect the transactions contemplated
hereby. Nothing in this Section 4.1(e) or
the certificate delivered pursuant hereto will limit or otherwise
affect AMI’s rights under Section 4.1(j)
.
(f)
Isis shall tender
to AMI a certificate representing the Remaining Shares duly and
validly endorsed for transfer in favor of AMI or accompanied by a
separate
17
stock power duly and validly
executed by Isis and otherwise sufficient to vest in AMI legal and
beneficial ownership of the Remaining Shares.
(g)
Isis and AMI
shall have received all other authorizations, consents, and
approvals of Governmental Authorities referred to in
Sections 5.1(c) and 5.1(d) .
(h)
Ibis shall have
the benefit of all Licenses necessary to conduct the Business as it
had been conducted prior to the Closing and as contemplated to be
conducted immediately thereafter.
(i)
Isis shall have
obtained (A) payoff letters for any Indebtedness of Ibis to be
paid by AMI on behalf of Isis at the Closing and (B) releases
of any and all Encumbrances on the Remaining Shares or the assets
of Ibis (except, with respect to the assets of Ibis, Permitted
Encumbrances), all on terms reasonably satisfactory to
AMI.
(j)
Since the
Investment Date, there shall have been no occurrence or disclosure
of any event, circumstance or state of facts which has, or would
reasonably be expected to have, a material adverse effect on the
business, assets, condition (financial or otherwise), operations,
operating results, employee relations, customer relations or
supplier relations of Ibis (a “ Material Adverse
Effect ”). Notwithstanding the foregoing or any
other provision in this Agreement to the contrary, the disclosures
set forth in the Disclosure Schedules shall not be considered in
determining whether the condition specified in this
Section 4.1(j) has been met.
(k)
Isis and Ibis
shall have executed and delivered to AMI the Transition Services
Agreement substantially in the form attached hereto as
Exhibit E , the terms of which shall provide that
(i) subject to Section 8.14 , in no event will AMI
and Ibis together be required to pay to Isis more than $[***] in
the aggregate for the Initial Services (as defined in the
Transition Services Agreement) provided by Isis thereunder,
(ii) Isis will provide only the categories of services set
forth on Exhibit E-1 attached hereto, and
(iii) Ibis will not occupy Isis’ facilities nor will
Isis be required to provide services to Ibis after [***] (the
“ Transition Services Agreement ”), and the
Transition Services Agreement shall be in full force and
effect.
(l)
Isis shall have
executed and delivered to AMI a non-foreign affidavit dated as of
the Closing Date and in form and substance required under the
Treasury Regulations issued pursuant to Code § 1445
stating that Isis is not a “Foreign Person” as defined
in Code § 1445.
(m)
There shall not
have been any material breach of any of the terms and provisions of
the Transaction Documents that has not been waived by
AMI.
(n)
Except as
contemplated by Section 2.5 and the Transition Services
Agreement, Ibis shall be entitled to fully exercise without
restriction or limitation all legal and beneficial rights under the
Ibis Contracts (including the Government Contracts) and all other
assets, properties and rights related to, used in or necessary to
operate and conduct the Business in all respects in the manner
conducted on and prior to the Closing Date and as contemplated to
be conducted from and after the Closing Date.
18
[***]AMI may waive any condition
specified in this Section 4.1 if it executes a writing
so stating at or prior to the Closing. In the event of any
such waiver, AMI shall be deemed to have waived any claim against
Isis for failure to satisfy such condition; provided that,
except to the extent specifically and expressly set forth in such
waiver, any such waiver shall not limit AMI’s right to
recovery hereunder for a breach by either Isis or Ibis of any other
provision of this Agreement.
4.2
Conditions to Obligation of
Isis . The
obligation of Isis to consummate the transactions to be performed
by it in connection with the Closing is subject to satisfaction of
the following conditions:
(a)
Each of the
representations and warranties of AMI set forth in this Agreement
shall be true and correct in all material respects at and as of the
date hereof and as of the Closing Date.
(b)
AMI shall have
performed and complied in all material respects with each of its
covenants hereunder through the Closing;
(c)
No Claim shall be
pending before any court, arbitrator, other body or administrative
agency of any Governmental Authority wherein an unfavorable
injunction, judgment, order, decree, ruling or charge would prevent
consummation of any of the transactions contemplated by this
Agreement (and no such injunction, judgment, order, decree, ruling
or charge shall be in effect).
(d)
All filings with
and authorizations and approvals of Governmental Authorities that
are required for the consummation of the transactions contemplated
hereby shall have been duly made and obtained on terms reasonably
satisfactory to Isis. Without limiting the generality of the
foregoing, all applicable waiting periods (and any extensions
thereof) under the HSR Act shall have expired or otherwise been
terminated.
(e)
AMI shall have
delivered to Isis a certificate of AMI to the effect that each of
the conditions specified above in Section 4.2(a)
and Section 4.2(b) is satisfied in all
respects.
(f)
AMI (and any
other Abbott Holders (as defined in the Investor Rights Agreement))
shall have executed and delivered to Isis a written consent in form
reasonably satisfactory to AMI and Isis, consenting to the
transactions contemplated by Section 7.10 .
Isis may waive any condition specified in this
Section 4.2 if it executes a writing so stating at or
prior to the Closing. In the event of any such waiver, Isis
shall be deemed to have waived any claim against AMI for failure to
satisfy such condition; provided that, except to the extent
specifically and expressly set forth in such waiver, any such
waiver shall not limit Isis’ right to recovery hereunder for
a breach by AMI of any other provision of this
Agreement.
19
Section 5.
REPRESENTATIONS AND
WARRANTIES.
5.1
Representations and Warranties of
Isis . As a material
inducement to AMI to enter into this Agreement, except as set forth
in the corresponding Section of the Disclosure Schedules
delivered to AMI herewith on the date hereof (the “
Disclosure Schedules ”), Isis hereby represents and
warrants the following representations and warranties are as of the
date hereof, and will be as of the Closing Date, true and
correct:
(a)
Power and
Authority . Each of Ibis and Isis
(i) has the power, authority and the legal right to enter into
each of the Transaction Documents and to perform its obligations
hereunder and thereunder, and (ii) has taken all necessary
action required to authorize the execution and delivery of each of
the Transaction Documents and the performance of its obligations
hereunder and thereunder.
(b)
Enforceability
. Each of the
Transaction Documents has been duly executed and delivered on
behalf of Ibis and Isis and constitutes a legal, valid and binding
obligation of each such Party and is enforceable against each such
Party in accordance with its terms subject to the effects of
bankruptcy, insolvency or other Laws of general application
affecting the enforcement of creditor rights.
(c)
Governmental
Authority; Consents . All necessary consents,
approvals and authorizations of all Governmental Authorities and
other parties required to be obtained by Ibis and Isis in
connection with the execution and delivery of each of the
Transaction Documents and the performance of their obligations
hereunder and thereunder have been obtained.
(d)
No
Conflicts . The execution and delivery
of each of the Transaction Documents by each of Ibis and Isis and
the performance of each such Party’s obligations hereunder
and thereunder, with or without the passage of time or giving of
notice, (i) do not and will not conflict with or violate any
requirement of Applicable Law or any provision of the certificate
of incorporation, bylaws or any similar instrument of such Party,
as applicable (ii) do not and will not require any notice,
conflict with, violate, or breach or constitute a default or
require any consent or give rise to any termination or acceleration
right or the creation of any Encumbrance on the Shares, the
Additional Shares or the Remaining Shares or any of the properties
or assets of Ibis under, any contractual obligation by which such
Party is bound or subject to and (iii) do not and will not
cause the suspension, revocation, impairment, forfeiture or
nonrenewal of any License applicable to Ibis, the Business or any
of Ibis’ operations, assets or properties.
(e)
Due
Organization; Qualification . Each of Ibis and Isis is a
corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware, with full corporate power
and authority to enter into each of the Transaction Documents.
Except as would not reasonably be expected to have a Material
Adverse Effect, Ibis has obtained and currently maintains all
qualifications to do business as a foreign corporation in all
jurisdictions in which the character of the Business requires it to
be so qualified. Ibis has all requisite power and authority and all
authorizations and Licenses necessary to own, operate or conduct
the Business.
20
(f)
Subsidiaries
. Ibis does not
own or control any Capital Stock or other interest of any Person.
Ibis is not a participant in any joint venture, partnership,
limited liability company or similar arrangement. Since its
inception Ibis has not merged with, acquired all or substantially
all of the assets of (except pursuant to the Contribution
Agreement) or acquired the Capital Stock of or any interest in any
Person. Ibis does not hold the right to acquire any Capital Stock
or interest in any other Person or have any obligation to make any
investment in any Person and no such rights, Capital Stock or
interests are necessary for the operation of the Business. Isis
does not control or possess the power, directly or indirectly to
control the management, actions or policies of Regulus
Therapeutics, LLC.
(g)
Capitalization; Voting
Rights .
(i)
The authorized
Capital Stock of Ibis consists of 1,228,501 shares of Common
Stock, par value $0.001 per share, 1,228,501 shares of which are
issued and outstanding, 1,000,000 of which are held by Isis and
228,501 shares of which are held by
AMI.
(ii)
The issued and
outstanding Capital Stock of Ibis as of the Closing will consist
exclusively of the Shares, the Additional Shares and the Remaining
Shares. Except as set forth in the Investor Rights Agreement, Ibis
does not have any obligations to issue or redeem any shares of
Capital Stock and Ibis has not issued any Capital Stock other than
the Shares, the Additional Shares and the Remaining Shares. No
Capital Stock issued by Ibis is listed on any stock exchange or
unregulated market. Other than the Transaction Documents, there are
no agreements with Isis or Ibis or any other Person with respect to
the voting or Transfer of the Remaining Shares.
(iii)
The Remaining
Shares are: (A) duly authorized, validly issued, fully paid
and nonassessable; (B) issued in compliance with all
applicable state and federal Laws concerning the issuance of
Capital Stock; and (C) free and clear of all Encumbrances
other than the Call Option; provided, that the Remaining
Shares may be subject to restrictions on Transfer under state
and/or federal securities Laws as set forth herein or as otherwise
required by such Laws at the time a Transfer is
proposed.
(iv)
The sale of the
Remaining Shares to AMI hereunder is not subject to any preemptive
rights, rights of first refusal or similar rights.
(h)
Agreements;
Liabilities .
(i)
There are no
judgments, orders, writs or decrees to which Ibis or Isis is a
party currently pending or, to Isis’ or Ibis’
Knowledge, threatened which would prevent Ibis or Isis from
entering into the Transaction Documents or issuing or Transferring
the Remaining Shares pursuant to the terms of the Transaction
Documents.
(ii)
Ibis has not
(A) accrued, declared or paid any dividends, or authorized or
made any distribution upon or with respect to any class or series
of its Capital Stock, (B) incurred or guaranteed any
Indebtedness (other than Permitted Indebtedness), (C) made any
loans or advances to any Person, other than advances for reasonable
travel expenses to Ibis employees in the ordinary course of
business, or
21
(D) sold,
exchanged, licensed or otherwise disposed of any of its tangible
assets, other than the sale of its inventory in the ordinary course
of business.
(iii)
Ibis has no
material obligations or liabilities (whether accrued, absolute, or
to Isis’ or Ibis’ Knowledge contingent, unliquidated or
otherwise, whether due or to become due and regardless of when or
by whom asserted), including, without limitation, Taxes, except
(A) obligations under the Ibis Contracts made available to AMI
or under Contracts entered into in the ordinary course of business
which, because of the dollar thresholds set forth in Sections
5.1(l) and 5.1(x) , are not required pursuant to
Sections 5.1(l) and 5.1(x) below to be
described on Schedules 5.1(l) or 5.1(x)
(but not liabilities for breaches of any such Contracts),
(B) liabilities reflected on the Most Recent Balance Sheet,
(C) liabilities and obligations which have arisen after the
date of the Most Recent Balance Sheet in the ordinary course of
business (none of which is material or is a liability for breach of
contract, tort, infringement (directly, contributorily, by
inducement or otherwise), Claim or warranty (other than warranty
claims arising in the ordinary course of business in connection
with the sale of Products or under Ibis Contracts made available to
AMI, none of which warranty claims individually or in the aggregate
would reasonably be expected to have a Material Adverse Effect) and
(D) other liabilities and obligations to the extent expressly
disclosed in Schedule 5.1(h)(iii) .
(i)
Obligations
to Related Parties . There are no obligations of
Ibis to Affiliates, officers, directors or employees of Ibis or
Isis other than (i) for payment of salary to employees of Ibis
for services rendered in the ordinary course of business,
(ii) reimbursement to employees of Ibis for reasonable
expenses incurred in the ordinary course of business on behalf of
Ibis, (iii) standard employee benefits made generally
available to all employees, pursuant to the Plans described on
Schedule 5.1(p)(ii) , (iv) the Bonus Arrangement or
(v) Ibis’ rights and obligations to Isis under the
Contribution Agreement and Corporate Services Agreement. To
Isis’ and Ibis’ Knowledge, all of the Contracts to
which Ibis is a party or by which the Business or any of its assets
is bound have been negotiated on an arms length basis.
(j)
Title to
Properties and Tangible Assets; Liens, Etc . Ibis has good and
marketable title to its properties and tangible assets and good and
valid title to its leasehold estates, in each case subject to no
Encumbrance other than (i) Permitted Encumbrances and
(ii) rights of the U.S. federal government in certain
equipment purchased using government funds, as set forth on
Schedule 5.1(j) . The tangible assets of Ibis have been
maintained in accordance with normal industry practice and are in
good operating condition and repair (except for ordinary wear and
tear).
(k)
Sufficiency
of Assets .
(i)
Except for the
services, funding and facilities provided under the Corporate
Services Agreement, Ibis has all assets, properties and rights used
in or necessary to operate or conduct the Business in all
respects.
(ii)
Except the
services, funding and facilities provided under the Corporate
Services Agreement and indirectly, via the Remaining Shares, Isis
and its Affiliates do not have any right, title or
22
interest in or to
any asset, property, title or interest that is used in or necessary
to operate or conduct the Business as conducted on and prior to the
Closing Date or as contemplated to be conducted by Ibis and Isis
after the Closing Date as reflected in the Offering Memorandum and
Management Presentations. Pursuant to the Contribution Agreement,
Isis has transferred to Ibis all assets, properties and rights Isis
owned or which are or were used in or necessary to operate or
conduct the Business except the services, funding and facilities
provided under the Corporate Services Agreement. No person employed
by the Division prior to the date of the Contribution Agreement is
currently employed by Isis and no former employee of Ibis or the
Division is or has been employed by Isis.
(l)
Intellectual
Property .
(i)
Schedule
5.1(l)(i) sets forth a complete
and correct list of all of the following Intellectual Property used
in or necessary to operate or conduct the Business (whether owned
by Ibis or any other Person), and indicates with respect to each
item, whether Ibis owns or licenses such Intellectual Property and
the owner of any Intellectual Property covered by such
license: (A) patented or registered Intellectual
Property and pending patent applications or other applications for
registrations of Intellectual Property (including jurisdiction,
registration and application number, as applicable, and record
owner), (B) registered and material unregistered trademarks,
service marks, trade names, and Internet domain names,
(C) Software (other than unmodified, commercially available,
off-the-shelf Software purchased or licensed for less than an
individual cost of [***] and a total cost of [***] in the aggregate
for all such licenses), (D) material algorithms embodied in
the Products and any other material trade secrets; and (E) all
other material Intellectual Property used in or necessary to
operate or conduct the Business (including, without limitation, all
Intellectual Property set forth or required to be set forth in the
following Schedules to the Contribution Agreement:
Schedule 2.1 (Ibis Business Assets), Schedule 2.2 (Ibis
Business Patents), Schedule 2.5 (Ibis Trademarks) and Schedule 2.6
(Ibis Business Software)) (all Intellectual Property described in
the foregoing, (A) through (E), collectively, (without regard
to whether such Intellectual Property is set forth on Schedule
5.1(l)(i) ) “ Business IP ”).
(ii)
Schedule
5.1(l)(ii) sets forth a complete
and correct list of all of the following Contracts (other than
licenses for unmodified, commercially available, off-the-shelf
Software purchased or licensed for less than an individual cost of
[***] and a total cost of [***] in the aggregate for all such
licenses) relating to the Business IP (collectively, the “
IP Contracts ”): (A) Contracts in which Ibis
or Isis or any of their respective Affiliates is a licensee or
sublicensee of Business IP; (B) Contracts in which Ibis or
Isis or any of their respective Affiliates is a licensor or
sublicensor of Business IP; (C) Contracts to which Ibis or
Isis or any of their respective Affiliates is a party, or by which
any of the Business IP is bound, that give any third party any
right, title or interest in or to any such Business IP;
(D) Contracts with any Governmental Authority wherein any
portion of the Business IP was developed or used (“
Government Contracts ”); and (E) Contracts that
restrict Ibis’ rights in or use or disclosure of Business
IP.
23
(iii)
Ibis owns and
possesses all right, title and interest in and to, free and clear
of all Encumbrances (other than the rights of Governmental
Authorities under Government Contracts identified in Schedule
5.1(l)(iii) to the Intellectual Property identified in
such Schedule) or has a valid and enforceable license to use
(pursuant to a written license agreement set forth and described in
Schedule 5.1(l)(ii) or a written license for
unmodified, commercially available, off-the-shelf Software
purchased or licensed for less than an individual cost of [***] and
a total cost of [***] in the aggregate) the Business
IP.
(iv)
Neither Isis nor
any of its Affiliates (other than Ibis) has any right, title or
interest in or to any of the Business IP.
(v)
To Isis’ or
Ibis’ Knowledge, neither Ibis, nor with respect to the
Business, Isis, has infringed (directly, contributorily, by
inducement or otherwise), misappropriated or otherwise conflicted
with, and the operation of the Business (including the development,
manufacture and commercialization of the T5000 Biosensor System,
the [***], and the assay kits specifically listed in the [***])
does not and will not infringe (directly, contributorily, by
inducement or otherwise), misappropriate or otherwise conflict
with, the patents, trademarks, copyrights or trade secrets of any
Person, and neither Ibis nor Isis is aware of any facts that
indicate a likelihood of any of the foregoing (including without
limitation, oral or written demands or offers to license any
Intellectual Property from any Person). With respect to whether the
operation or conduct of the Business has or will infringe
(directly, contributorily, by inducement or otherwise),
misappropriate or otherwise conflict with patent, trademark,
copyright or trade secrets of any Person (other than Ibis or Isis
or their respective Affiliates), the Parties hereto are relying
upon the representations and warranties contained in this
Section 5.1(l)(v) and not the representations and
warranties contained in Sections 5.1(k)(i) ,
5.1(l)(viii)
or
5.1(l)(ix) .
(vi)
All of the
Business IP is valid and to Isis’ or Ibis’ Knowledge
enforceable. Isis and Ibis have taken all necessary actions to
maintain and protect all of the Business IP, including, without
limitation, entering into confidentiality agreements with each of
its employees, consultants and independent contractors, and
customers and vendors as necessary so as not to adversely affect
the validity or enforceability thereof and have complied with
disclosure requirements as provided by any Government Contract.
Neither Ibis nor Isis has disclosed any source code for any
Software included in the Business IP to any Person in a manner that
would impair the trade secret or other Intellectual Property
protection of such source code. There are no claims, oppositions or
cancellation proceedings that either were made or brought within
the past [***] years, or are presently pending or, to Isis’
or Ibis’ Knowledge, threatened, against either Ibis or Isis
contesting the validity, use, ownership, enforceability or
registrability of any Business IP. Neither Ibis nor Isis is aware
of any basis for any such claim, opposition or cancellation
proceeding, and neither Ibis nor Isis has received any notices
regarding any of the foregoing. No loss or expiration of any
material Business IP is pending or reasonably foreseeable or, to
Isis’ or Ibis’ Knowledge, threatened, except for
patents expiring at the end of their statutory terms (and not as a
result of any act or omission by either Ibis or Isis, including,
without limitation, a failure to pay any required maintenance fees)
or limitations to the scope of claims of any pending patent
application
24
made during the
ordinary course of prosecuting such pending patent applications.
Complete copies of all file histories for issued patents and
pending patent applications of the Business IP owned or held by
either Ibis or Isis have been provided to AMI.
(vii)
To Isis’ or
Ibis’ Knowledge, (A) no Person has infringed (directly,
contributorily, by inducement or otherwise) or misappropriated any
of the Business IP and (B) no Person is infringing (directly,
contributorily, by inducement or otherwise) or misappropriating any
of the Business IP.
(viii)
Ibis has
sufficient right, title and interest in and to the Business IP:
(A) to conduct the Business, including the development,
manufacture and commercialization of the T5000 Biosensor System
(including the [***] and the assay kits specifically listed in the
[***] on a worldwide basis, with no payment obligation to any
Person, except pursuant to an IP Contract, and (B) to make,
have made, import, use , offer for sale,
or sell any
product (including [***] currently marketed by the Business and the
assay kits specifically listed in the [***] without infringing
(directly, contributorily, by inducement or otherwise),
misappropriating or conflicting with any Intellectual Property
rights of any Person. The Business IP is and will be as of the
Closing Date, owned by or available for use by Ibis on terms and
conditions identical to those under which it was owned or used by
Ibis and the Business prior to the date hereof.
(ix)
To Isis’ or
Ibis’ Knowledge, Ibis has sufficient right, title and
interest in and to the Business IP: (A) to develop,
manufacture and commercialize the [***] on a worldwide basis, with
no payment obligation to any Person, except pursuant to an IP
Contract made available to AMI, and (B) to make, have made,
import, use, offer for sale, or sell the [***] without infringing
(directly, contributorily, by inducement or otherwise),
misappropriating or conflicting with any Intellectual Property
rights of any Person.
(x)
No funding,
facilities or resources of a Governmental Authority, university,
college, other educational institution or research center or
funding from third parties was used in the development of any of
the Business IP and no Governmental Authority, university, college,
other educational institution or research center has any claim or
right in or to any of the Business IP.
(xi)
Each current or
former employee of each Isis Party or any of their respective
Affiliates, who was involved in, or who contributed to, the
creation or development of any Business IP, executed the standard
form of proprietary rights agreement set forth in Schedule
5.1(l)(xi) upon commencement of his or her employment and each
such current or former employee and any consultant or independent
contractor who was involved in, or who contributed to, the creation
or development of any Business IP has validly assigned all right,
title and interest in and to such Business IP to Ibis.
(xii)
None of the
Transaction Documents nor the transactions contemplated by any of
the Transaction Documents would result in or reasonably be expected
to result in: (A) Ibis, AMI or any of their respective
Affiliates granting to any Person any right to or with respect to
any Intellectual Property owned by, or licensed to,
25
any of them as a
result of any Encumbrance or Contract to which, Ibis or any of
their Affiliates is a party or bound by, (B) other than
standard non-solicitation agreements entered into in the ordinary
course of business and made available to AMI, Ibis, AMI or any of
their respective Affiliates being bound by, or subject to, any
non-compete or other material restriction on the operation or scope
of their respective businesses as a result of any Encumbrance or
Contract to which Isis, Ibis or any of their Affiliates is a party
or bound by, (C) other than as contemplated by the Acquisition
Agreement, Ibis, AMI or any of their respective Affiliates being
obligated to pay any royalties or other material amounts, to
increase or accelerate any royalty or payment obligation, or to
offer any discounts, to any Person as a result of any Encumbrance
or Contract to which Isis, Ibis or any of their Affiliates is a
party or bound by, or (D) any adverse effect on Ibis’
right, title or interest in and to any of the Business
IP.
(xiii)
All components of
the current version of the T5000 Biosensor System perform in all
material respects in accordance with their currently advertised,
displayed, distributed or published specifications. All services
that have been performed in the conduct of the Business were
performed in material conformity with the terms and requirements of
the related Contracts and all Applicable Laws. All Software
included in the Business IP is free of any disabling codes or
instructions, timer, copy protection device, clock, counter or
other limiting design or routing and any “back door,”
“time bomb,” “Trojan horse,”
“worm,” “drop dead device,”
“virus” or other similar disabling codes, Software
routines or hardware components. No open source, public source or
other Software that is licensed pursuant to a license that purports
to require the distribution of, or access to, source code or
purports to restrict one’s ability to charge for distribution
of Software (including, without limitation, any version of any
Software licensed pursuant to any GNU general public license or
limited general public license or other Software), was used in,
incorporated into, integrated or bundled with any Software that has
been used in the T5000 Biosensor System or any other product that
has been distributed or is currently distributed. Ibis does not
have any plans to include any such Software in any such system or
Product. The source code for all Software included in the Business
IP is sufficiently documented such that a software programmer of
ordinary skill would be able to maintain and modify such source
code using reasonable efforts.
(xiv)
Without limiting
any other representation or warranty herein, the computer and other
information technology systems and networks owned or contracted for
by Ibis have been maintained in accordance with normal industry
practice, are in good operating condition and repair (except for
ordinary wear and tear) and are sufficient for the operation of the
Business. Each of Ibis and Isis has taken all reasonably necessary
action to safeguard the computer and other information technology
systems and networks used in the operation of the Business and
there has been no unauthorized intrusions or breaches of the
security of the computer and other information technology systems
and networks used in the Business that have materially compromised
or are currently materially compromising the security, integrity or
operations of such systems or networks.
(xv)
The individuals
identified as the outside counsel involved in the development or
prosecution of the Business IP on Schedule 1(rr) represent
the
26
outside counsel
who have provided Isis or Ibis strategic legal and Intellectual
Property advice related to the Business IP and the Ibis Business
during the three (3) years prior to the Closing
Date.
(m)
Compliance
with Other Instruments . Neither Ibis nor, with
respect to the Business, Isis is in violation or default of any
term of its charter documents, each as amended, or of any provision
of any Contract to which it is party or by which the Business is
bound or of any judgment, decree, order or writ.
(n)
Litigation
. There is no
Claim pending or, to Isis’ or Ibis’ Knowledge,
threatened against Ibis or, with respect to the Business, Isis (or
against any Ibis or Isis employee (in their capacity as such)), at
Law or in equity, or before or by any Governmental Authority, and
to Isis’ or Ibis’ Knowledge, there is no reasonable
basis for any of the foregoing. Neither Ibis nor, with respect to
the Business, Isis is subject to any outstanding order, judgment,
or decree issued by any Governmental Authority or any arbitrator.
Neither Ibis nor any of its Affiliates has received any opinion or
memorandum or advice from legal counsel to the effect that Ibis or
the Business is or was exposed, from a legal standpoint, to any
material liability.
(o)
Tax
Matters .
(i)
Ibis has filed
all required Tax Returns. All Taxes owed and due by Ibis have been
paid. No claim has ever been made by an authority in any
jurisdiction that Ibis is or may be subject to taxation by that
jurisdiction. There are no Encumbrances on any of the assets used
by Ibis that arose in connection with any failure (or alleged
failure) to pay any Tax. Schedule 5.1(o)(i) contains a
list of states, territories and jurisdictions (whether foreign or
domestic) in which Ibis is required to file Tax
Returns.
(ii)
Ibis has withheld
and paid all Taxes required to have been withheld and paid in
connection with amounts paid or owing by Ibis to any employee,
independent contractor, creditor, stockholder, or other third
party, and all Forms W-2 and 1099 required with respect thereto
have been properly completed.
(iii)
There is no
dispute or claim concerning any Tax liability of Ibis either
(A) claimed or raised by any Governmental Authority or
(B) as to which Isis or Ibis has Knowledge.
(iv)
Neither Ibis nor,
with respect to the Business, Isis, has waived any statute of
limitations in respect of Taxes or agreed to any extension of time
with respect to a Tax assessment or deficiency.
(v)
To Isis’ or
Ibis’ Knowledge based in good faith on advice of
Deloitte & Touche LLP, (A) Ibis and Isis are and will
be members of the same consolidated group, as such term is defined
by Treasury Regulation § 1.1502-1(h), with Isis being the
common parent of such consolidated group for all taxable years
through and including the Closing and (B) unless the
provisions of the Code pertaining to filing Tax Returns as a
consolidated group are amended prior to the Closing, Ibis and Isis
will be eligible to file a consolidated Tax Return in lieu of
separate Tax Returns with respect
27
to income Tax
imposed by Chapter 1 of the Code for all taxable years through and
including the Closing.
(vi)
Ibis is not and
will not at the Closing be a party to any oral or written Tax
sharing agreements or arrangements.
(p)
Employees
.
(i)
Neither Ibis nor,
with respect to the Business, Isis, is party to any collective
bargaining agreement. There is no labor union organizing activity
pending or, to Isis’ or Ibis’ Knowledge, threatened
with respect to Ibis. Each of Ibis and, with respect to the
Business, Isis has complied with all applicable Laws relating to
the employment of labor and, within the last five (5) years,
neither Ibis nor Isis, with respect to the Business, has
experienced any strike, work stoppage, lockout, grievance, unfair
labor practice claim or other labor relation problem, including,
without limitation, any written dispute with or Claim by former
employees regarding termination and/or severance pay. To the
Knowledge of Isis or Ibis, no executive, key employee or group of
employees of Ibis has any plans to terminate employment with Ibis.
In the past three (3) years, Ibis and Isis have complied in
all respects with the notification provisions (or paid severance in
lieu thereof) of the WARN Act and applicable similar state or local
laws. No executive, key employee or group of employees of Ibis or
the Business has been terminated or resigned their employment since
the Investment Date.
(ii)
Schedule
5.1(p)(ii) contains a true and
complete list of each employment (other than at-will offer letters
with no severance, compensation term guarantee or material
benefit), bonus, fringe benefit, deferred compensation, incentive
compensation, stock purchase, stock option, stock appreciation
right or other stock-based incentive, severance, change-in-control,
or other termination pay, hospitalization or other medical,
disability, life or other insurance, supplemental unemployment
benefits, profit-sharing, pension, or retirement plan, program or
Contract and each other employee benefit plan, program or Contract
sponsored, maintained or contributed to or required to be
contributed to by Ibis, or by any trade or business, whether or not
incorporated (an “ ERISA Affiliate ”), that
together with Ibis or Isis would be deemed a “single
employer” under Section 414(b), (c), (m) or
(o) of the Code, for the benefit of any current or former
employee or director of Ibis (the “ Plans ”).
Schedule 5.1(p)(ii) identifies each Plan that is an
“employee welfare benefit plan” or “employee
pension benefit plan” as such terms are defined in Sections
3(1) and 3(2) of ERISA (such plans being hereinafter
referred to collectively as the “ ERISA Plans
”).
(iii)
Except as
specified in Section 8.11(d) , neither Ibis nor Isis
has any formal plan or binding commitment to create any additional
Plan or modify or change any existing Plan that would affect any
current or former employee or director of Ibis, except as required
by Applicable Law or to conform such Plan to the requirements of
any Applicable Law. Except for the Master Agreement and this
Agreement, there are no Contracts or omissions that would prevent
or impair any Plan (including any Plan covering retirees or other
former employees) from being amended or terminated by Ibis or Isis
prior to or at the Closing, or, with respect to the Plans listed on
Schedule 5.1(p)(xii)
28
if any, by Ibis
or AMI (or any successor thereto) on or at any time after the
Closing.
(iv)
Neither Isis nor
Ibis has incurred and has no reason to expect that either will
incur any liability to the Pension Benefit Guaranty Corporation
(other than premium payments) or otherwise under Title IV of ERISA
(including any withdrawal liability) or under the Code or any
Applicable Law with respect to any employee pension benefit plan
that Isis or Ibis, or any other entity that together with Isis or
Ibis is treated as a single employer under Section 414 of the
Code, maintains or ever has maintained or to which it contributes,
ever has contributed, or ever has been required to
contribute.
(v)
Neither Ibis nor
Isis, nor any of the ERISA Plans, nor any trust created thereunder,
nor to Isis’ or Ibis’ Knowledge, any trustee or
administrator thereof has engaged in a transaction or has taken or
failed to take any action in connection with which Ibis could be
subject to any material liability for either a civil penalty
assessed pursuant to Sections 409 or 502(i) of ERISA or a
tax imposed pursuant to Sections 4975, 4976 or 4980B of the
Code.
(vi)
Each Plan is in
all material respects in compliance, and has been administered in
all material respects in accordance, with the applicable provisions
of ERISA, the Code and all other Applicable Laws, including, but
not limited to, medical continuation under
Section 4980B of the Code. Neither Isis nor
Ibis has (A) engaged in any transaction prohibited by ERISA or
the Code; (B) breached any fiduciary duty owed by it with
respect to the Plans; or (C) failed to file and distribute
timely and properly all reports and information required to be
filed or distributed in accordance with ERISA or the
Code.
(vii)
Other than
routine claims for benefits, there are no Claims, Internal Revenue
Service or Department of Labor compliance programs or other
proceedings pending or, to Isis’ or Ibis’ Knowledge,
threatened against or otherwise involving any Plan.
(viii)
Each Plan which
is intended to be qualified under Section 401(a) of the
Code (A) has been amended to reflect all requirements under
the Code which are required to be adopted prior to the end of the
applicable remedial amendment period and (B) has received from
the Internal Revenue Service a favorable determination letter which
considers the terms of the Plan as amended for such changes in
Law.
(ix)
None of the Plans
obligates Isis or Ibis either (A) to pay any separation,
severance, termination or similar benefit to Ibis Employees or
(B) to make an excess parachute payment within the meaning of
Code Section 280G.
(x)
No Plan provides
benefits, including without limitation death or medical benefits
(whether or not insured), with respect to current or former
employees of Ibis after retirement or other termination of service
(other than (A) coverage mandated by any Applicable Law,
(B) death benefits or retirement benefits
29
under any
employee pension benefit plan or (C) benefits, the full direct
cost of which are borne by the current or former employee (or
beneficiary thereof)).
(xi)
To Isis’ or
Ibis’ Knowledge, other than as provided under the terms of
the Plans, neither Ibis nor Isis has made any representation or
commitment to, or entered into any formal or informal understanding
with, any Ibis employee with respect to compensation, benefits, or
terms of employment to be provided by AMI or Ibis or any of their
respective Affiliates at or subsequent to the Closing.
(xii)
Except for the
Bonus Arrangement, Ibis neither sponsors nor maintains nor has any
liability for (A) any of the Plans or (B) any other
employee benefit plans or arrangements.
(xiii)
All
contributions, premiums or payments under or with respect to each
Plan which are or were due have been paid.
(q)
Compliance
with Laws; Licenses .
(i)
Ibis, the
Business and, with respect to the Business, Isis are not in
material violation of any Law. Ibis, the Business, and, with
respect to the Business, Isis and Ibis’ and Isis’
Representatives have complied with, and are in material compliance
with, all Applicable Laws, including, without limitation, the
federal Food, Drug, and Cosmetic Act, as amended and regulations
promulgated thereunder, and all U.S. Food and Drug Administration
(“ FDA ”) or its foreign equivalent regulations
governing, among other things, the protection of human subjects and
regulations governing clinical investigators. No governmental
orders, permissions, consents, approvals or authorizations are
required to be obtained and no registrations or declarations are
required to be filed in connection with the execution and delivery
of the Transaction Documents or the Transfer of the Remaining
Shares.
(ii)
Ibis holds all
Licenses necessary for the operation or conduct of the Business
(including pursuant to Environmental Laws). Schedule
5.1(q)(ii) sets forth a list of all Licenses material to
the Business (the “ Material Licenses ”). Ibis
is and has been in compliance with all terms and conditions of such
Material Licenses and all Material Licenses may be relied upon by
Ibis immediately following the Closing for the lawful operation of
the Business as conducted on and prior to the date hereof. Each
Material License is valid, binding and in full force and effect and
Ibis and the Business have complied in all material respects with
all requirements of and are not in default under any Material
License and have not received written or, to Isis’ or
Ibis’ Knowledge, oral notice that the Business or Ibis is in
violation of any of the terms or conditions of such Material
License. No loss or suspension of any License nor any proceeding or
investigation which is seeking such a loss or suspension is pending
or, to Isis’ or Ibis’ Knowledge, threatened. Neither
Ibis nor Isis is operating under any written or oral formal or
informal agreement or understanding with any licensing authority,
Regulatory Authority or any other Governmental Authority which
restricts the conduct of the Business or requires Ibis or, with
respect to the Business, Isis, to take or refrain from taking any
actions.
30
(r)
Environment,
Health and Safety . Ibis and the Business have
at all times materially complied with and are in material
compliance with all Environmental Laws, including, without
limitation, all Licenses and other authorizations that are required
pursuant to Environmental Laws for the ownership and occupation of
the assets used by Ibis and the operation of the Business. Neither
Ibis nor Isis, with respect to the Business is aware of or has
reason to be aware of or has received any notice, request for
information, report, order, directive, communication or other
information, written or oral, regarding any actual or alleged
violation of Environmental Laws, or any Claims or other liabilities
or potential liabilities (whether accrued, absolute, contingent,
unliquidated or otherwise) arising under Environmental Laws,
relating to the Business, the Real Property or Ibis, which has not
been resolved without liability to Ibis. Neither Ibis nor its
Affiliates nor any of its legal predecessors has, in violation of
Environmental Laws, treated, stored, disposed of, arranged for or
permitted the disposal of, transported, handled, or Released, or
exposed any Person to, any Hazardous Materials, or owned or
operated any property or facility (and no such property or facility
including the Real Property is contaminated by any such Hazardous
Materials) so as to give rise to any current or future liability
under Environmental Laws, including without limitation, any
liability to investigate, remediate, cleanup, monitor or take any
similar actions with respect to the environmental condition of any
property (whether owned or non-owned), facility or treatment,
storage or disposal facility. None of the following exists or to
Isis’ or Ibis’ Knowledge, has ever existed at the Real
Property: underground storage tanks, septic tanks, asbestos
containing materials, polychlorinated biphenyls, lead-based paint,
urea-formaldehyde, dumps, landfills, or waste disposal areas,
sumps, pits, lagoons, surface impoundments or wetlands, or any
contamination of any kind of the surface, subsurface, groundwater
or surface water. Ibis has not assumed or become subject to,
whether expressly or by operation of Law, any liabilities of any
other Person arising under Environmental Laws or pursuant to any
type of agreement. The consummation of the transactions
contemplated by this Agreement do not impose any obligation on the
Business under any Environmental Law or require notification to or
consent of any Governmental Authority or third party pursuant to
any Environmental Law. Ibis has provided to AMI copies of all
material environmental Licenses, reports, audits, assessments, and
investigations, and any other material environmental documents,
relating to Ibis or the Business to the extent the foregoing are in
the possession, custody, or control of Isis or any of its
Affiliates or Ibis.
(s)
Offering
Valid . Assuming the accuracy of
the representations and warranties of AMI contained in
Section 5.2 hereof, the offer and sale of the Remaining
Shares will be exempt from the registration requirements of the
Securities Act, and will have been registered or qualified (or are
exempt from registration and qualification) under the registration,
permit or qualification requirements of all applicable state
securities Laws. Neither Isis nor any agent on its behalf has
solicited or will solicit any offers to sell or
|